Regeneron Pharmaceuticals vs Vertex Pharmaceuticals
Regeneron Pharmaceuticals reported revenue of $14.3 billion in fiscal 2025, 1.2 times Vertex Pharmaceuticals' $12.0 billion in fiscal 2025. Regeneron Pharmaceuticals' revenue grew 1.0% in its latest year, and Vertex Pharmaceuticals' grew 8.9%. Regeneron Pharmaceuticals had an operating margin of 24.9%, against 34.8% at Vertex Pharmaceuticals. Free cash flow was $4.1 billion at Regeneron Pharmaceuticals and $3.2 billion at Vertex Pharmaceuticals.
Side by side
| Regeneron Pharmaceuticals | Vertex Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $14.3B | $12.0B |
| Revenue growth | 1.0% | 8.9% |
| Revenue growth a year, last 5 years | 11.0% | 14.1% |
| Gross margin | — | 86.2% |
| Operating margin | 24.9% | 34.8% |
| Net margin | 31.4% | 32.9% |
| Free cash flow | $4.1B | $3.2B |
| Free cash flow margin | 28.4% | 26.6% |
| Return on capital | 12.7% | 31.5% |
| Net debt to EBITDA | −1.4x | −1.5x |
| Dividends and buybacks | $3.8B | $2.0B |
| Change in diluted share count | −5.7% | 0.0% |
| Last close | $807.67 | $517.49 |
| P/E at the last close | 20.0× | 30.1× |
| Insider trades, last 12 months | sold $16.1 million | sold $158.1 million |
| Piotroski F-score | 5 of 8 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Regeneron PharmaceuticalsVertex Pharmaceuticals
Operating margin
Percent of revenue
Regeneron PharmaceuticalsVertex Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Regeneron PharmaceuticalsVertex Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Regeneron Pharmaceuticals and Vertex Pharmaceuticals pages.